桂枝茯苓胶囊联合地诺孕素对子宫腺肌症的CA125、MDM2、VEGF表达水平的影响  

Effect of Guizhi Poria Capsule Combined with Dinorgestrel on the Expression Levels of CA125,MDM2 and VEGF in Adenomyosis of Uterus

作　　者：朱丹 张凤格 刘坤 郝婷 ZHU Dan;ZHANG Feng-ge;LIU Kun;HAO Ting(Department of Gynaecology,Shunyi Maternity and Childcare Hospital of Beijing,Beijing 101300,China)

机构地区：[1]北京市顺义区妇幼保健院,北京顺义101300

出　　处：《药物生物技术》2023年第4期398-402,共5页Pharmaceutical Biotechnology

基　　金：首都卫生发展科研专项项目(首发2022⁃3⁃7102)。

摘　　要：探讨桂枝茯苓胶囊联合地诺孕素在子宫腺肌症中的应用,及对糖类抗原125(CA125)、鼠双微基因2(MDM2)、血管内皮生长因子(VEGF)表达水平的影响。选择2021年1月至2022年6月,北京市顺义区妇幼保健院收治的98例子宫腺肌症患者为研究对象,按随机数字表法均分为两组(对照组、观察组,各49例),实施桂枝茯苓胶囊治疗,观察组再加上地诺孕素进行联合治疗。比较两组的血清指标水平(CA125、MDM2、VEGF)、激素指标水平[雌二醇(E_(2))、促卵泡激素(FSH)、黄体生成素(LH)]、病症改善情况及炎性因子水平[视觉模拟评分法(VAS)、子宫内膜厚度、C反应蛋白(CRP)、子宫体积、血红蛋白(HB)]、不良反应、临床疗效。观察组治疗后3个月的CA125、MDM2、VEGF、E_(2)、FSH、LH、CRP值及VAS评分、子宫内膜厚度、子宫体积均低于对照组,观察组治疗后3个月的HB值、总有效率高于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。在子宫腺肌症中实施桂枝茯苓胶囊联合地诺孕素治疗,能降低CA125、MDM2、VEGF表达水平,改善激素水平,减轻痛经症状,缓解子宫内膜异常增生及炎性反应,提升临床疗效,且具有一定安全性,值得在临床中推广应用。To investigate the application of Guizhi Fuling Capsules combined with dinorgestrel in the treatment of uterine adenomyo⁃sis,and the effect on the expression levels of carbohydrate antigen 125(CA125),mouse double microgene 2(MDM2)and vascular endothelial growth factor(VEGF),from January 2021 to June 2022,98 patients with uterine adenomyosis admitted to the Maternal and Child Health Hospital of Shunyi District Beijing were selected as the study subjects,which were divided into two groups(control group,observation group,49 cases each),and the observation group plus dienorgestin for combination treatment.Compare the two groups of serum levels(CA125,MDM2,VEGF),hormone levels[estradiol(E_(2)),follicle⁃stimulating hormone(FSH),luteinizing hormone(LH)],disease improvement and inflammatory factor levels[visual analog scoring method(VAS),endometrial thickness,C reactive protein(CRP),uterine volume,hemoglobin(HB)],adverse reactions and clinical efficacy.The values of CA125,MDM2,VEGF,E_(2),FSH,LH,CRP,VAS score,endometrial thickness and uterine volume in the observation group were lower than those in the control group at 3 months after treatment,while the HB value and total effective rate in the observation group were higher than those in the control group at 3 months after treatment,with statistical significance(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The combination of Guizhi Fuling Capsules and Dinorectin in the treatment of adenomyosis can reduce the expression levels of CA125,MDM2,and VEGF,improve hormone levels,alleviate dysmenorrhea symptoms,alleviate endometrial hyperplasia and inflammatory reactions,enhance clinical efficacy,and have certain safety,which is worth promoting and applying in clinical practice.

关 键 词：子宫腺肌症 桂枝茯苓胶囊 地诺孕素 糖类抗原 鼠双微基因 血管内皮生长因子 临床疗效 

分 类 号：R714[医药卫生—妇产科学]